Chimeric Therapeutics Limited (ASX: CHM)
Health Care · Biotechnology · AU
AU$0.04
-14.63% today · -91.3% 1Y
Chimeric Therapeutics Limited (ASX: CHM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.52M and employs 3 people.
Over the last twelve months the share price has lost 91.3%, trading between 0.04 and 0.40.
Tweenvest scores Chimeric Therapeutics Limited across four factors: quality 18/100, value 37/100. Its strongest factor is value.
CHM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.52M
- Revenue (TTM)
- $6.50M
- P/E
- —
- EPS
- -0.76
- Dividend yield
- —
- Beta (5Y)
- 0.71
- 52-week high
- AU$0.40
- 52-week low
- AU$0.04
- Avg volume (3M)
- —
- Shares outstanding
- 61.31M
- Employees
- 3
- Next earnings
- —
About Chimeric Therapeutics Limited
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
- ISIN
- AU0000121576
- Founded
- 2020
- Listed since
- Jan 17, 2021
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.29 | +0.67% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.02 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.42 | +1.14% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $554.25 | +1.22% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $836.21 | +0.93% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $156.85 | +12.93% |
Figures last refreshed Aug 18, 2026.